Business Profile & Competitive Position
The Cooper Companies, Inc. is a Healthcare company in the Medical – Instruments & Supplies industry. It operates through two segments: CooperVision, which makes contact lenses and specialty eyecare products, and CooperSurgical, which supplies fertility and women’s health products and services. CooperVision’s portfolio includes silicone hydrogel lenses, myopia management products such as the MiSight 1 day lens, orthokeratology lenses, and scleral lenses. CooperSurgical offers medical devices for gynecology, obstetrics, contraception, and labor and delivery, plus cord blood/tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.
The company reports a net margin of 13.5% and a return on equity of 6.9%. A double-digit net margin in a medical-device business points to meaningful pricing power and manufacturing scale, especially on the CooperVision side where single-use and specialty lenses carry strong recurring-revenue characteristics. The ROE, however, is relatively modest for a company with this margin profile, which can happen when a substantial equity base is supporting significant goodwill or acquisition-driven assets — CooperSurgical’s “strategic transactions” language in its 10-K is consistent with that interpretation. MiSight 1 day is FDA-, Chinese NMPA–, and Japanese MHLW–approved to slow myopia progression and correct vision in age-appropriate children, giving CooperVision a differentiated product with regulatory validation in the three largest healthcare markets, though the data provided does not quantify its revenue contribution.
Financial Posture
The Cooper Companies currently carries a market capitalization of approximately $12.1 billion and trades at a P/E ratio of 21.8. The net margin of 13.5% and ROE of 6.9% together suggest a profitable but capital-intensive business. The beta is 0.82, indicating lower volatility than the broad market, which is typical for a healthcare consumables company with recurring demand.
At a 21.8x trailing earnings multiple, the stock is priced as a stable grower rather than a deep-value or hyper-growth name. The 13.5% net margin is healthy but not exceptional for a specialty medical-device company, and the 6.9% ROE implies the business is not generating outsized returns on its equity base relative to higher-margin peers. This combination is consistent with a company that is profitable and defensive but where investors are weighing growth reinvestment, acquisition integration, and potential margin compression against the durability of contact-lens and fertility cash flows.
Strategic Priorities & Outlook
According to the company’s most recent 10-K filing, CooperVision is prioritizing broader worldwide market penetration of recently introduced products, expanding its presence in existing and emerging markets, and increasing investment in distribution and packaging capabilities to support growth and service quality. It is also investing to develop the myopia management market by educating eye care practitioners, patients, and their families. On the CooperSurgical side, the company expects to continue investing in the business, including through strategic transactions, as it builds an integrated solutions model within fertility and women’s health.
These priorities frame Cooper as a business pursuing organic share gains in vision care while using M&A to deepen its women’s health platform. The emphasis on distribution and packaging capacity suggests management sees volume growth ahead and wants to avoid operational bottlenecks. The myopia-management education push indicates the company is trying to expand the total addressable market for MiSight rather than simply capture share of an existing pool.
Macro & Geopolitical Exposure
As a Medical – Instruments & Supplies company, The Cooper Companies sits in a sector exposed to regulatory oversight, trade policy, currency movements, and supply-chain logistics. Contact lenses and surgical devices are regulated by the FDA and foreign equivalents, so labeling, manufacturing quality, and approval pathways create compliance costs that can affect margins. The MiSight product’s approvals in the United States, China, and Japan illustrate how geopolitical exposure is not abstract: access to the Chinese and Japanese markets depends on maintaining relationships with the NMPA and MHLW and navigating any trade or data-localization requirements that could affect product registration or distribution.
Currency risk is another real factor because Cooper sells products in more than 130 countries; a stronger U.S. dollar would reduce the reported value of overseas sales. Raw-material and freight costs also matter for a business shipping small, high-volume consumables globally. Finally, fertility and women’s health services can be influenced by regulatory changes, reimbursement policy, and demographic trends in birth rates and family-planning utilization.
Recent Developments
The most recent news flow has been dominated by securities litigation announcements. On November 8, 2026, Rosen Law Firm encouraged Cooper Companies investors to inquire about a securities class action investigation, according to newsfilecorp.com. Similar notices appeared on November 6, 2026, via globenewswire.com and on November 5, 2026, via prnewswire.com, all from the same law firm and focused on investor losses. These filings do not mean any claim has been proven, but they create headline and legal-overhang risk for a stock heading into an earnings report.
Separately, CooperCompanies announced on November 5, 2026, that it will release fourth quarter and full year 2026 results on December 3, 2026 — after the market close. That release is now the next scheduled earnings event, with consensus EPS at $1.07.
Earnings Behavior & Post-Earnings Drift
Over the last eight reported quarters, The Cooper Companies has beaten earnings estimates every time, for a 100% beat rate, with an average positive surprise of 4.2%. Despite that flawless beat record, the average 5-day price move after earnings has been -2.34%, classified as a downward drift. This is the central disconnect in the data: the company routinely exceeds the official consensus, yet the stock has not reliably rewarded those beats.
The last four reports make this pattern especially clear. On September 9, 2026, Cooper reported actual EPS of $1.15 versus an estimate of $1.12, a 2.7% positive surprise, but the stock fell 14.67% the next day and 13.97% over the following five days. On June 4, 2026, actual EPS of $1.21 beat the $1.10 estimate by 10%, and the stock rose 8.58% the next day and 8.85% over the following five days. On March 5, 2026, actual EPS of $1.10 beat the $1.03 estimate by 6.8%, yet the stock dropped 4.55% the next day and 10.82% over the following five days. On December 4, 2025, actual EPS of $1.15 beat the $1.11 estimate by 3.6%, and the stock rose 5.67% the next day and 6.59% over the following five days.
What stands out is that beats alone have not determined direction. Two of the last four beats produced strong gains, while the other two produced sharp losses, including one where the company beat estimates but sold off nearly 15% in a single session. This suggests the market’s real expectation may have been higher than the published consensus, or that forward guidance and segment commentary mattered more than the headline EPS number. For traders and investors focused on earnings events, the actionable lesson is not whether Cooper will beat — it has done so for eight straight quarters — but whether the reported results and guidance clear the unofficial consensus embedded in the stock price. Heading into the December 3, 2026 report, the official consensus is $1.07, but the post-earnis history suggests the reaction will depend on how that result compares with what investors actually expect.
For a deeper dive into how institutional analysts are currently weighing CooperVision’s myopia opportunity, CooperSurgical’s deal activity, and the potential legal overhang, explore the full institutional verdict and consensus breakdown for COO.
Frequently Asked Questions
What does The Cooper Companies actually sell?
The company operates two segments: CooperVision, which develops and markets contact lenses and specialty eyecare products including the MiSight 1 day myopia-management lens, and CooperSurgical, which provides medical devices, services, and solutions for fertility and women’s health.
How has the stock historically reacted after earnings?
Over the last eight quarters, COO has beaten EPS estimates 100% of the time with an average positive surprise of 4.2%. However, the average 5-day post-earnings move has been -2.34%, meaning beats have not reliably produced sustained gains.
What strategic priorities has management highlighted?
In its most recent 10-K, the company emphasized expanding CooperVision’s market penetration, investing in distribution and packaging, building the myopia-management market through education, and pursuing strategic transactions to grow CooperSurgical’s integrated fertility and women’s health platform.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-09-09 | $1.15 | $1.12 | +2.7% | -14.67% | -13.97% |
| 2026-06-04 | $1.21 | $1.1 | +10% | +8.58% | +8.85% |
| 2026-03-05 | $1.1 | $1.03 | +6.8% | -4.55% | -10.82% |
| 2025-12-04 | $1.15 | $1.11 | +3.6% | +5.67% | +6.59% |
| 2025-08-27 | $1.1 | $1.07 | +2.8% | - | - |
| 2025-05-29 | $0.96 | $0.928 | +3.4% | - | - |
Previous COO editions
Get the institutional verdict on COO
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the COO verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.